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Abstract Treatment of U937 cells with dolichyl phosphate led 
to an increase in the activity of the ICE family protease CPP32, 
accompanied with cleavage of pre-CPP32 to generate pl7 . 
Pep tide inhibitors YVAD-cmk and Z-Asp-CH2-DCB (specific to 
ICE) and D E V D - C H O (specific to CPP32) blocked the dolichyl 
phosphate-induced apoptosis. The dolichyl phosphate-induced 
increase of CPP32 activity was inhibited by adenylate cyclase 
inhibitors, SQ 22536 and 2',5'-dideoxyadenosine. Dolichyl 
phosphate caused a transient increase of intracellular cAMP 
concentration. The results suggest that modulation of cAMP 
synthesis due to the stimulation of adenylate cyclase by dolichyl 
phosphate plays a critical role in CPP32 activation and 
apoptosis. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Recent studies have strongly implicated the interleukin-l(3-
converting enzyme (ICE)/CED-3 family of cysteine proteases 
as key participants in the apoptotic cell death that can occur 
during development [1,2], due to ligation of the FAS (CD95) 
or tumor necrosis factor (TNF) receptors [3-7], trophic factor 
deprivation [8] and a number of other apoptosis-inducing 
stimuli [9-11]. In mammals , the ICE/CED-3 family includes 
several members, which have been divided into at least three 
subfamilies with homology to the prototype proteases ICE, 
CPP32, and Ich-1 [12]. The protease subfamilies have distinct 
substrate specificities [13], and different kinetics of activation 
after delivery of an apoptotic signal [14]. The effects of these 
proteases in apoptosis appear to be manifested via the cleav-
age of key homeostatic cellular substrates, including poly 
(ADP-ribose) polymerase [9] and R B protein [15]. 
Previously we found that dolichyl phosphate induces apop-
totic changes, including nuclear fragmentation and internu-
cleosomal cleavage of genomic D N A [16]. However, the 
mechanism of intracellular delivery of the dolichyl phos-
phate-induced apoptotic signal is unknown. In the present 
study, we have examined the effect of dolichyl phosphate on 
an ICE/CED-3 family cysteine protease, CPP32. Since dolich-
yl phosphate activated CPP32, we then examined the effects of 
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adenylate cyclase inhibitors, such as SQ 22536 and 2',5'-di-
deoxyadenosine (DDA). The results together with the transi-
ent increase of adenosine 3',5'-cyclic monophosphate (cAMP) 
suggest that stimulation of c A M P synthesis plays an impor-
tant role in CPP32 activation and in the dolichyl phosphate-
induced apoptotic pathway. 
2. Materials and methods 
2.1. Materials 
Dolichyl phosphate was kindly provided by the Tsukuba Research 
Laboratories of Eisai Company. Acetyl-Asp-Glu-Val-Asp-oc-(4-meth-
ylcoumaryl-7-amide) (DEVD-MCA), acetyl-Tyr-Val-Ala-Asp-cc-(4-
methylcoumaryl-7-amide) (YVAD-MCA) and 7-amino-4-methylcou-
marin (AMC) were purchased from Peptide Institute, Inc. (Osaka, 
Japan). ICE inhibitor II (Ac-Tyr-Val-Ala-Asp-chloromethylketone; 
YVAD-cmk), ICE inhibitor III (benzyloxycarbonyl-Asp-CH2OC(0)-
2,6-dichlorobenzene; Z-Asp-CH2-DCB), apopain (CPP32) inhibitor 
(Ac-Asp-Glu-Val-aspartic acid aldehyde; DEVD-CHO) and DNA mo-
lecular weight standard pHY marker were from Takara (Kyoto, Ja-
pan). 9-(Tetrahydro-2-furanyl)-9H-purin-6-amine (SQ 22536) was 
from Research Biochemicals International (Maine, USA), 2',5'-di-
deoxyadenosine (DDA) from Calbiochem Novabiochem (California, 
USA). Mouse monoclonal anti-CPP32 antibody was from Transduc-
tion Laboratories (Kentucky, USA). Cyclic AMP EIA system was 
from Amersham (Little Chalfont, England). 
2.2. Cell culture and induction of apoptosis 
Human promonocytic leukemia U937 cells were routinely cultured 
at 37°C in RPMI 1640 containing 10% fetal calf serum, using stand-
ard cell culture procedures. Cells were washed and resuspended at 
2X 106 cells/ml in the same medium, and cultured in the absence or 
presence of dolichyl phosphate dissolved in ethanol:dodecane (98:2, 
v/v). The concentration of ethanokdodecane was 1% in the culture 
medium and the presence of the solvent caused neither CPP32 activa-
tion nor DNA fragmentation. Cells were incubated for the indicated 
time at 37°C, collected, and washed with ice-cold phosphate-buffered 
saline. 
2.3. Inhibitors 
The effect of protease inhibitors (YVAD-cmk, Z-Asp-CH2-DCB 
and DEVD-CHO) and adenylate cyclase inhibitors (SQ 22536 and 
DDA) on dolichyl phosphate-induced apoptosis were evaluated. 
YVAD-cmk and Z-Asp-CH2-DCB were dissolved in dimethyl sulfox-
ide (DMSO). DEVD-CHO, SQ 22536 and DDA were dissolved in 
distilled water. The final concentration of DMSO was less than 
0.2%, a level which was confirmed to have no influence on the exper-
imental outcome. Inhibitors were added to the medium at the indi-
cated time prior to the treatment with dolichyl phosphate. 
2.4. Analysis of DNA fragmentation by agarose gel electrophoresis 
DNA from whole cell populations, incubated in the presence or 
absence of dolichyl phosphate and/or protease inhibitor for 8 h, was 
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extracted and electrophoresed on 1. 7% Nusieve:agarose (3:1) gels as 
described in our previous paper [17]. Each experiment was repeated at 
least three times. 
2.5. CPP32- and ICE-like protease assays 
Cysteine protease activity was measured using a modified procedure 
of Walker et al. [18]. Briefly, cells were lysed in buffer containing Tris-
HC1 (pH 7.5) and 0.2% Triton X-100 for 30 min on ice, and clarified 
by centrifugation. Enzyme reaction mixtures contained 50 uM fluo-
rescent substrate, DEVD-MCA or 100 uM YVAD-MCA and the cell 
lysate (approximately 150 u.g protein). The reaction performed in 50 
mM Tris-HCl (pH 7.0), 0.5 mM EDTA, 1 mM dithiothreitol, 20% 
glycerin and 0.1% Triton X-100. Fluorescent AMC product formation 
was measured with excitation at 380 nm and emission at 460 nm using 
a Cytofluor II plate reader (Perseptive Biosystems). Protease activity 
was expressed as AMC cleaved per mg protein per minute. 
2.6. Western blotting 
For anti-CPP32 immunoblots, cell lysates (50 u.g protein/lane) were 
separated on 14% SDS-polyacrylamide gels under reducing condi-
tions, transferred to nitrocellulose membrane, and probed with mouse 
monoclonal anti-CPP32 followed by goat anti-mouse antibody 
coupled to horseradish peroxidase. Products were visualized using 
the ECL system (Amersham). 
2.7. cAMP assay 
Cyclic AMP was extracted and quantitated by enzyme immunoas-
say system with anti-cAMP antibody, according to the manufacturer's 
instructions. Cyclic AMP was extracted from cells by ice-cold 65% 
ethanol. The extracted material was dried under the stream of argon 
gas. Cyclic AMP content was expressed as fmol of cAMP per 106 
cells. 
3. Results and discussion 
3.1. Effect of inhibitors of ICE/CED-3 family proteases on 
dolichyl phosphate-induced DNA fragmentation 
When U937 cells were continuously treated with 20 ug/ml 
of dolichyl phosphate, more than 90% of the cells died within 
10 h, as determined by using the WST (water soluble-tetrazo-
lium salt) assay method, an improved MTT (3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cell prolif-
eration assay (data not shown). DNA fragmentation 
characteristic of apoptosis occurred within 8 h after the treat-
ment with dolichyl phosphate (Fig. 1). To examine the in-
volvement of ICE/CED-3 family proteases in the induction 
of apoptosis by dolichyl phosphate, we studied the effect of 
inhibitors of ICE/CED-3 family proteases on the DNA frag-
mentation induced by dolichyl phosphate. The inhibitors used 
were a peptide chloromethylketone YVAD-cmk, an aspartate-
based protease inhibitor Z-Asp-CH2-DCB and an aldehyde 
DEVD-CHO. YVAD-cmk [19], which was developed initially 
as an irreversible ICE inhibitor, can also inhibit CPP32 and 
other ICE-like proteases [9]. Z-Asp-CH2-DCB can inhibit ICE 
and other proteases which cleave the residues next to Asp, 
including Ich-1 and granzyme B [20]. DEVD-CHO inhibits 
CPP32 as well as several ICE/CED-3 family members, includ-
ing MCH3, which is closely related to CPP32 [21]. All of these 
inhibitors showed a very efficient protection of the cells from 
dolichyl phosphate-induced DNA fragmentation (Fig. 1) and 
morphological changes typical of apoptosis (data not shown). 
Treatment of U937 cells with DEVD-CHO, YVAD-cmk or Z-
Asp-CH2-DCB at the same concentration did not cause DNA 
fragmentation. The inhibitory effect of YVAD-cmk in this 
paper is in contrast to the report showing that apoptosis of 
U937 cells caused by anti-FAS and TNF-oc cytotoxicity is not 
prevented by YVAD-cmk [6]. These data suggest that CPP32 
1 2 3 4 5 6 
Fig. 1. Effect of inhibitors of ICE-like proteases on dolichyl phos-
phate-induced DNA cleavage. Cells were incubated at 37 for 2 h in 
either control medium (lanes 2 and 3), or in medium supplemented 
with either 600 uM YVAD-cmk (lane 4), 200 uM Z-Asp-CH2-DCB 
(lane 5) or 600 uM DEVD-CHO (lane 6). Then, 15 ug/ml dolichyl 
phosphate (lanes 3, 4, 5 and 6) or ethanol :dodecane (98:2, v/v) 
(lane 2) was added and incubation was continued for 8 h. DNA 
samples were prepared and electrophoresed as described in the text. 
Lane 1, pHY markers (4870, 2016, 1360, 1107, 926, 658, 489 and 
267 bp). 
and/or other ICE-like proteases are involved in apoptotic cell 
death induced by dolichyl phosphate, and that the signal 
transduction cascade of dolichyl phosphate is, at least in 
part, different from those associated with apoptosis induced 
by anti-FAS or TNF. 
3.2. Dolichyl phosphate-induced CPP32-like activity 
Fig. 2 shows that dolichyl phosphate activates CPP32-like 
activity in a dose- and time-dependent manner. In a time 
course experiment with dolichyl phosphate at the concentra-
tion of 20 u.g/ml for up to 5 h, CPP32-like activity was not 
detected for 1 h, then increased up to 3 h, and thereafter 
decreased gradually (Fig. 2A). The CPP32-like activity in-
creased with increase of dolichyl phosphate concentration 
from 2.5 to 7.5 |J.g/ml. Induction of activity was maximum 
at the concentration of 10 u.g/ml, when the cells were incu-
bated for 3 h (Fig. 2B). Half-maximal induction of CPP32-like 
activity occurred with about 4 |ig/ml dolichyl phosphate. The 
maximal level of the induction of CPP32-like activity was 
about 7-8 times that of the control experiment with an equiv-
alent amount of ethanol:dodecane (98:2, v/v). 
In contrast to CPP32, ICE-like activity was not detectable 
in the experiment using 50 or 100 U.M YVAD-MCA as a 
substrate following dolichyl phosphate stimulation of U937 
cells. Similar results have been obtained for ICE activity 
stimulated by FAS in Jurkat cells [22]. 
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Fig. 2. Time course and dose-response relation of dolichyl phos-
phate-induced CPP32-like protease activity. (A) Cells were incubated 
for the indicated times in the presence of dolichyl phosphate (20 ag/ 
ml). (B) Cells were incubated for 3 h in the presence of dolichyl 
phosphate at the indicated concentration. Protease activity was as-
sayed using 50 uM DEVD-MCA (•) or 100 uM YVAD-MCA (o) 
as the substrate and expressed as pmol AMC cleaved per mg pro-
tein per min. All values are the mean ± S.D. of triplicate determina-
tions made in parallel. 
3.3. Dolichyl phosphate-induced CPP32 activation 
CPP32 normally exists in cytosol as an inactive precursor 
Table 1 
The effects of adenylate cyclase inhibitors on dolichyl phosphate-in-
duced CPP32 activity 
Inhibition of CPP32 activity (%) 
SQ 22536 
DDA 
73.0 ±15.4 
74.5 ±25.3 
Cells were incubated at 37°C in either control medium, or in medium 
supplemented with 5 mM SQ 22536 or 5 mM DDA for 15 min. Then, 
dolichyl phosphate (10 ug/ml) was added. CPP32 activity was deter-
mined 2 h after dolichyl phosphate treatment and expressed as a 
percentage of the appropriate control under each experimental con-
dition. Values are the mean ± S.D. of 3-4 different experiments. 
and only appears as the active form when cells are undergoing 
apoptosis. Erhardt and Cooper demonstrated that PI-3 kinase 
inhibitors (wortmannin and LY294002) and etoposide convert 
CPP32 into the active pl7 subunit, while treatment with TNF-
cc resulted in the accumulation of p20 subunit in U937 cells 
[23]. As shown in Fig. 3, 17-kDa peptide was scarcely detect-
able at 0 h, but detectable after 2 h and was clearly evident 
after 3 h treatment. Thus, the 32-kDa pro-CPP32 was con-
verted to the 17-kDa peptide characteristic of active CPP32 by 
dolichyl phosphate treatment. 
3.4. Involvement of adenylate cyclase in dolichyl 
phosphate-induced CPP32 activation 
Inhibitors of adenylate cyclase (SQ 22536 and DDA) were 
used to examine the participation of the cAMP pathway in 
dolichyl phosphate-induced apoptosis (Table 1). CPP32 acti-
vation induced by dolichyl phosphate was decreased to 25-
27% of the original level when cells were preincubated with 
5 mM SQ 22536 and 5 mM DDA. Treatment of U937 cells 
with SQ 22536 or DDA alone had no effect on CPP32 activ-
ity. In addition, SQ 22536 or DDA itself (up to 50 uM) did 
not show any change in CPP32 activity in vitro. We further 
examined the effect of dolichyl phosphate on cellular cAMP 
concentrations in U937 cells. As shown in Fig. 4, dolichyl 
phosphate (15 |xg/ml) caused a transient increase in the intra-
cellular levels of cAMP, from a basal level of approximately 
500 fmol to greater than 750 fmol/106 cells within 60 min. 
These results suggest that the elevation of intracellular 
cAMP concentration by dolichyl phosphate is a key event in 
the induction of apoptosis. 
The intracellular level of cAMP can be modulated in several 
Mw (kDa) 
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Fig. 3. Time course of dolichyl phosphate-induced CPP32 activation. Cells were incubated for 2 h (lane 2) or 3 h (lane 3) in the presence of 
dolichyl phosphate (15 ug/ml). Proteins were then extracted and separated by SDS-PAGE, followed by western blotting and probing for anti-
CPP 32 antibody. Lane 1, 0 time. 
156 Y. Yokoyama et al.lFEBS Letters 412 (1997) 153-156 
Time (min) 
Fig. 4. Time course of dolichyl phosphate-induced modulation of in-
tracellular cAMP levels. Cells were incubated for the indicated times 
in the presence of dolichyl phosphate (15 u,g/ml). Intracellular 
cAMP levels were measured by enzyme immunoassay and expressed 
as fmol cAMP per 106 cells as described in the text. Results shown 
are representative of three independent experiments. 
ways, i.e. by (i) stimulation of adenylate cyclase with a drug 
such as forskolin, (ii) increase of cAMP mediated by steroid 
hormones and PGE1 [24], (iii) accumulation of cAMP 
through a receptor-coupled mechanism, and (iv) addition of 
membrane-permeable cAMP analogues. Elevation of cAMP 
by drugs, such as forskolin [25], gliotoxin [26], erythromycin 
and dibutyryl cAMP (Bt2cAMP) [27] leads to apoptotic cell 
death. In contrast, inhibition of cAMP synthesis by ceramide 
[28], radiation [29] and serum deprivation [30] also induces 
apoptotic cell death in a variety of cells. In these cases, the 
cells can be rescued by the addition of cell-permeable 
Bt2cAMP. 
It has been shown that the cellular level of dolichyl phos-
phate and its derivatives may limit cell division by controlling 
the numbers of functional receptors for growth factors via 
glycosylation of the receptors [31]. However, we showed pre-
viously that inhibitors of the N-linked glycosylation mediated 
by dolichyl phosphate did not affect the apoptotic cell death 
[16]. The molecular mechanism by which dolichyl phosphate 
induces cAMP synthesis is not yet known. It is conceivable 
that dolichyl phosphate increases the level of intracellular 
cAMP either by direct interaction with adenylate cyclase or 
through receptor-mediated mechanisms. Overall, the results 
imply that cAMP accumulation induced by dolichyl phos-
phate is an important step in the induction of apoptotic cell 
death. The fine turning of apoptosis might be regulated by a 
concerted action of cAMP mediated signals induced by sev-
eral drugs and antibodies described above and some other 
mechanisms such as growth factors and hormones which exert 
their effects in a cAMP independent manner. The precise 
understanding of the role of the factors and the cross talk 
systems between the different signals that induce apoptosis 
remains for further investigation. 
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